Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental Bapineuzumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bapineuzumab SC Dose 1; 2 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 2; 7 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 3; 20 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Experimental Bapineuzumab | DRUG | Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiv...
Top 20 of 30 competitors
Experimental Bapineuzumab is an investigational monoclonal antibody developed by Johnson & Johnson for Alzheimer's disease. It was studied as a subcutaneous treatment in a Phase 2 clinical trial. It is not an approved therapy and remains in clinical development.
Experimental Bapineuzumab was studied for the treatment of mild to moderate Alzheimer's disease. The Phase 2 trial enrolled 146 participants with this condition. It is an investigational agent and has not been approved for any indication.
Experimental Bapineuzumab is developed by Johnson & Johnson, which trades under the ticker symbol JNJ. The company sponsored the Phase 2 clinical trial evaluating the drug in Alzheimer's disease.
Experimental Bapineuzumab is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. The drug is investigational and has not received FDA approval.
Experimental Bapineuzumab was evaluated in a single Phase 2 trial, NCT01254773, titled "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease." The trial was completed, enrolled 146 participants, and was conducted in the United States.